partnerScore 50/100Research
Google DeepMind building foundational AI infrastructure for drug discovery; Isomorphic spun out to commercialize AlphaFold applications in chemistry space
Demis Hassabis· Google DeepMind· AI· 2026-07-06· about Isomorphic Laboratories
“we spun out companies like Isomorphic off the back of AlphaFold to do drug discovery and it's going really well and build sort of you know you can think of build additional AlphaFold type type systems to go into chemistry space to help accelerate drug design”
Why it matters
Isomorphic represents a picks-and-shovels play on AlphaFold's protein-folding capability extending into pharmaceutical R&D acceleration, creating demand for computational infrastructure and potentially enabling faster drug discovery pipelines.
Investment implication
Investors should track Isomorphic's progress as a leading AI drug-discovery platform. Success would drive adoption among pharma firms and biotech, increasing demand for GPU compute, high-bandwidth data infrastructure, and specialized lab equipment.